Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMONO add-on therapy for depressive symptoms in nursing-home residents with neurocognitive disorders
2023-504691-18-00Phase 2Authorised
- Sponsor
- CHRU Tours
- Start
- Apr 2024
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nitrous oxide + oxygen in major depressive disorder (MDD) and Dementia (2 arms), sponsored by CHRU Tours. Primary endpoint: Primary: Change in Cornell depression scale from baseline to week 4. Planned start Apr 2024; status: authorised.
02
Drugs
nitrous oxide + oxygen
03
Conditions
major depressive disorder (MDD)Dementia
Beyond the preview
Go deeper on 2023-504691-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504691-18-00.